Partial Gland Ablation of Prostate Cancer: Effects of Repeat Treatment
To evaluate the near-term clinical and pathological effects of repeat partial gland ablation (PGA) in men with intermediate-risk prostate cancer (PCa). One hundred seventy men with focal lesions of PCa (all GG2 or GG3) underwent PGA with high-intensity focused ultrasound (HIFU) or cryotherapy (CRYO)...
Saved in:
| Published in | Urology (Ridgewood, N.J.) Vol. 170; pp. 161 - 167 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.12.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0090-4295 1527-9995 1527-9995 |
| DOI | 10.1016/j.urology.2022.07.024 |
Cover
Loading…
| Abstract | To evaluate the near-term clinical and pathological effects of repeat partial gland ablation (PGA) in men with intermediate-risk prostate cancer (PCa).
One hundred seventy men with focal lesions of PCa (all GG2 or GG3) underwent PGA with high-intensity focused ultrasound (HIFU) or cryotherapy (CRYO) in prospective trials. Residual PCa in or near the ablation zone was found in 37 men after a first PGA; 30 went on to receive a second PGA and were the subjects of study. At 3 timepoints, baseline and 6 months after first and second ablations, quality-of-life (QOL) questionnaires (IIEF, IPSS) and MRI-guided biopsies (MRGB) were performed. Biopsies were targeted and systematic at baseline and in follow-up, comprehensively about the ablation zone.
All 30 patients completed QOL questionnaires and 26 had MRGB at the 3 timepoints. Mean QOL scores were not significantly different from the baseline after the first or second PGA. No operative complications were encountered; and “decisional regret” was reported in only 2/29 men after the repeat ablation. A decrease in semen volume was reported by 25% of patients. Repeat ablation was successful (absence of csPCa on MRGB) in 14/26 (53%) of men. PSA levels decreased and MRI lesions resolved after ablations, but neither was a reliable predictor of biopsy outcomes.
When initial PGA fails, repeat PGA is a reasonable consideration, because in near-term follow-up, secondary procedures appear to be safe, causing only minimal detriment to urinary and sexual function, with csPCa becoming undetectable by MRGB in approximately half the patients. |
|---|---|
| AbstractList | To evaluate the near-term clinical and pathological effects of repeat partial gland ablation (PGA) in men with intermediate-risk prostate cancer (PCa).
One hundred seventy men with focal lesions of PCa (all GG2 or GG3) underwent PGA with high-intensity focused ultrasound (HIFU) or cryotherapy (CRYO) in prospective trials. Residual PCa in or near the ablation zone was found in 37 men after a first PGA; 30 went on to receive a second PGA and were the subjects of study. At 3 timepoints, baseline and 6 months after first and second ablations, quality-of-life (QOL) questionnaires (IIEF, IPSS) and MRI-guided biopsies (MRGB) were performed. Biopsies were targeted and systematic at baseline and in follow-up, comprehensively about the ablation zone.
All 30 patients completed QOL questionnaires and 26 had MRGB at the 3 timepoints. Mean QOL scores were not significantly different from the baseline after the first or second PGA. No operative complications were encountered; and “decisional regret” was reported in only 2/29 men after the repeat ablation. A decrease in semen volume was reported by 25% of patients. Repeat ablation was successful (absence of csPCa on MRGB) in 14/26 (53%) of men. PSA levels decreased and MRI lesions resolved after ablations, but neither was a reliable predictor of biopsy outcomes.
When initial PGA fails, repeat PGA is a reasonable consideration, because in near-term follow-up, secondary procedures appear to be safe, causing only minimal detriment to urinary and sexual function, with csPCa becoming undetectable by MRGB in approximately half the patients. To evaluate the near-term clinical and pathological effects of repeat partial gland ablation (PGA) in men with intermediate-risk prostate cancer (PCa).OBJECTIVETo evaluate the near-term clinical and pathological effects of repeat partial gland ablation (PGA) in men with intermediate-risk prostate cancer (PCa).One hundred seventy men with focal lesions of PCa (all GG2 or GG3) underwent PGA with high-intensity focused ultrasound (HIFU) or cryotherapy (CRYO) in prospective trials. Residual PCa in or near the ablation zone was found in 37 men after a first PGA; 30 went on to receive a second PGA and were the subjects of study. At 3 timepoints, baseline and 6 months after first and second ablations, quality-of-life (QOL) questionnaires (IIEF, IPSS) and MRI-guided biopsies (MRGB) were performed. Biopsies were targeted and systematic at baseline and in follow-up, comprehensively about the ablation zone.MATERIALS AND METHODSOne hundred seventy men with focal lesions of PCa (all GG2 or GG3) underwent PGA with high-intensity focused ultrasound (HIFU) or cryotherapy (CRYO) in prospective trials. Residual PCa in or near the ablation zone was found in 37 men after a first PGA; 30 went on to receive a second PGA and were the subjects of study. At 3 timepoints, baseline and 6 months after first and second ablations, quality-of-life (QOL) questionnaires (IIEF, IPSS) and MRI-guided biopsies (MRGB) were performed. Biopsies were targeted and systematic at baseline and in follow-up, comprehensively about the ablation zone.All 30 patients completed QOL questionnaires and 26 had MRGB at the 3 timepoints. Mean QOL scores were not significantly different from the baseline after the first or second PGA. No operative complications were encountered; and "decisional regret" was reported in only 2/29 men after the repeat ablation. A decrease in semen volume was reported by 25% of patients. Repeat ablation was successful (absence of csPCa on MRGB) in 14/26 (53%) of men. PSA levels decreased and MRI lesions resolved after ablations, but neither was a reliable predictor of biopsy outcomes.RESULTSAll 30 patients completed QOL questionnaires and 26 had MRGB at the 3 timepoints. Mean QOL scores were not significantly different from the baseline after the first or second PGA. No operative complications were encountered; and "decisional regret" was reported in only 2/29 men after the repeat ablation. A decrease in semen volume was reported by 25% of patients. Repeat ablation was successful (absence of csPCa on MRGB) in 14/26 (53%) of men. PSA levels decreased and MRI lesions resolved after ablations, but neither was a reliable predictor of biopsy outcomes.When initial PGA fails, repeat PGA is a reasonable consideration, because in near-term follow-up, secondary procedures appear to be safe, causing only minimal detriment to urinary and sexual function, with csPCa becoming undetectable by MRGB in approximately half the patients.CONCLUSIONWhen initial PGA fails, repeat PGA is a reasonable consideration, because in near-term follow-up, secondary procedures appear to be safe, causing only minimal detriment to urinary and sexual function, with csPCa becoming undetectable by MRGB in approximately half the patients. |
| Author | Kwan, Lorna Nassiri, Nima Richardson, Shannon Felker, Ely Brisbane, Wayne G. Kuppermann, David Gonzalez, Samantha Marks, Leonard S. Wallner, Caroline |
| Author_xml | – sequence: 1 givenname: Nima surname: Nassiri fullname: Nassiri, Nima – sequence: 2 givenname: Shannon surname: Richardson fullname: Richardson, Shannon – sequence: 3 givenname: David surname: Kuppermann fullname: Kuppermann, David – sequence: 4 givenname: Wayne G. surname: Brisbane fullname: Brisbane, Wayne G. – sequence: 5 givenname: Samantha surname: Gonzalez fullname: Gonzalez, Samantha – sequence: 6 givenname: Lorna surname: Kwan fullname: Kwan, Lorna – sequence: 7 givenname: Ely surname: Felker fullname: Felker, Ely – sequence: 8 givenname: Caroline surname: Wallner fullname: Wallner, Caroline – sequence: 9 givenname: Leonard S. surname: Marks fullname: Marks, Leonard S. email: lmarks@mednet.ucla.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35907484$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkFFr2zAUhcXoaJOsP2HFj32xJ8uybG2UUkKSDgotJXsWN_J1UaZYmaQM8u-nLOlLX9oXXdA950jnG5OzwQ1IyNeSFiUtxbd1sfPOupd9wShjBW0KyvgnMipr1uRSyvqMjCiVNOdM1hdkHMKaUiqEaM7JRVVL2vCWj8j8CXw0YLOFhaHL7lYWonFD5vrsybsQIWI2hUGj_57N-h51DIfdM24RYrb06dzgEL-Qzz3YgJenOSG_5rPl9D5_eFz8nN495LqqeMw1cNkh4xJAilW661A2GlnV9LICrjVDygHqtm-FFtBhJVrZ8hWv-rpBkNWEXB9zt9792WGIamOCRps-j24XFBNStIKXrE3Sq5N0t9pgp7bebMDv1Wv3JPhxFOhUNHjslTbxf_vowVhVUnUgrdbqRFodSCvaqEQ6ues37tcH3vPdHn2YMP016FXQBhPgzvhEV3XOvJtw8yZBWzMYDfY37j_g_wfZDrA6 |
| CitedBy_id | crossref_primary_10_1002_cam4_5692 crossref_primary_10_1038_s41391_023_00715_w crossref_primary_10_1177_15330338231155000 |
| Cites_doi | 10.1016/j.eururo.2018.06.006 10.1016/S0090-4295(02)01643-6 10.1111/bju.15004 10.1016/j.juro.2013.12.036 10.1016/j.eururo.2021.08.005 10.1016/j.urolonc.2011.02.014 10.1111/bju.14710 10.1016/j.juro.2017.06.078 10.1186/s12957-015-0753-9 10.1038/s41391-020-00315-y 10.1016/j.urology.2015.11.018 10.1089/end.2016.0830 10.1016/j.clgc.2019.11.009 10.1016/j.eururo.2015.06.046 10.1016/j.eururo.2020.05.018 10.1016/j.juro.2017.08.085 10.1016/j.juro.2017.04.017 10.1097/JU.0000000000001133 10.1097/JU.0000000000001327 10.1007/s00345-018-2363-y 10.1097/JU.0000000000001787 10.1016/j.eururo.2013.03.025 10.1097/MOU.0000000000000052 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Inc. Copyright © 2022 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2022 Elsevier Inc. – notice: Copyright © 2022 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.urology.2022.07.024 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-9995 |
| EndPage | 167 |
| ExternalDocumentID | 35907484 10_1016_j_urology_2022_07_024 S0090429522006173 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA195505 – fundername: NCATS NIH HHS grantid: UL1 TR000124 |
| GroupedDBID | --- --K --M -RU .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAEJM AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJJEV AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEA HMK HMO HVGLF HZ~ IHE J1W KOM L7B LZ2 M29 M41 MO0 N9A O-L O9- OAUVE OK. OW. OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SPCBC SSH SSZ T5K UV1 WH7 WOW WUQ X7M XPP Z5R ZGI ~G- AACTN AAIAV ABLVK ABYKQ ACRZS AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW EFLBG LCYCR RIG ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c334t-ca49de249aa96bc33de97ce237f93a4cc2e04aa58f86c6ade368984b43f57ea93 |
| IEDL.DBID | .~1 |
| ISSN | 0090-4295 1527-9995 |
| IngestDate | Fri Jul 11 15:55:12 EDT 2025 Thu Apr 03 07:10:56 EDT 2025 Thu Apr 24 22:55:22 EDT 2025 Tue Jul 01 04:01:04 EDT 2025 Fri Feb 23 02:37:41 EST 2024 Tue Aug 26 19:32:38 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | Copyright © 2022 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c334t-ca49de249aa96bc33de97ce237f93a4cc2e04aa58f86c6ade368984b43f57ea93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 35907484 |
| PQID | 2696864128 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2696864128 pubmed_primary_35907484 crossref_citationtrail_10_1016_j_urology_2022_07_024 crossref_primary_10_1016_j_urology_2022_07_024 elsevier_sciencedirect_doi_10_1016_j_urology_2022_07_024 elsevier_clinicalkey_doi_10_1016_j_urology_2022_07_024 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | December 2022 2022-12-00 20221201 |
| PublicationDateYYYYMMDD | 2022-12-01 |
| PublicationDate_xml | – month: 12 year: 2022 text: December 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Urology (Ridgewood, N.J.) |
| PublicationTitleAlternate | Urology |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Tay, Polascik, Elshafei, Tsivian, Jones (bib0024) 2017; 31 Jarow, Ahmed, Choyke, Taneja, Scardino (bib0013) 2016; 88 Mustafa, Delacroix, Ward, Pisters (bib0017) 2015; 13 Chuang, Kinnaird, Kwan (bib0014) 2020; 204 Berge, Dickinson, McCartan (bib0018) 2014; 191 Tay, Amin, Ghai (bib0019) 2019; 37 Natarajan, Marks, Margolis (bib0010) 2011; 29 Borges, Tourinho-Barbosa, Glina (bib0016) 2021; 205 Shah, Reddy, Peters (bib0021) 2021; 24 Stabile, Sanchez-Salas, Tourinho-Barbosa (bib0004) 2021; 206 Jones, Chin, Mcleod, Barkin, Pantuck, Marks (bib0015) 2018; 199 Lebastchi, George, Polascik (bib0003) 2020; 78 Guillaumier, Peters, Arya (bib0023) 2018; 74 Epstein, Zelefsky, Sjoberg (bib0025) 2016; 69 Onik, Narayan, Vaughan, Dineen, Brunelle (bib0001) 2002; 60 Tan, ElShafei, Aminsharifi, Khalifa, Polascik (bib0009) 2020; 18 Nassiri, Chang, Lieu (bib0012) 2018; 199 Sonn, Chang, Natarajan (bib0011) 2014; 65 Natarajan, Jones, Priester (bib0022) 2017; 198 Hopstaken, Bomers, Sedelaar, Valerio, Fütterer, Rovers (bib0002) 2022; 81 Stabile, Orczyk, Hosking-Jervis (bib0005) 2019; 124 Barret, Harvey-Bryan, Sanchez-Salas, Rozet, Galiano, Cathelineau (bib0006) 2014; 24 Aminsharifi, Polascik (bib0007) 2019; 2 Lovegrove, Peters, Guillaumier (bib0008) 2020; 125 Lovegrove, Peters, Guillaumier (bib0020) 2020; 125 Priester AM. Why does Focal Therapy for Prostate Cancer Fail? Manuscr Press, Los Angeles, 2022. Hopstaken (10.1016/j.urology.2022.07.024_bib0002) 2022; 81 Sonn (10.1016/j.urology.2022.07.024_bib0011) 2014; 65 Tan (10.1016/j.urology.2022.07.024_bib0009) 2020; 18 Guillaumier (10.1016/j.urology.2022.07.024_bib0023) 2018; 74 Berge (10.1016/j.urology.2022.07.024_bib0018) 2014; 191 Mustafa (10.1016/j.urology.2022.07.024_bib0017) 2015; 13 Lovegrove (10.1016/j.urology.2022.07.024_bib0008) 2020; 125 Natarajan (10.1016/j.urology.2022.07.024_bib0010) 2011; 29 Stabile (10.1016/j.urology.2022.07.024_bib0005) 2019; 124 10.1016/j.urology.2022.07.024_bib0026 Tay (10.1016/j.urology.2022.07.024_bib0024) 2017; 31 Chuang (10.1016/j.urology.2022.07.024_bib0014) 2020; 204 Lebastchi (10.1016/j.urology.2022.07.024_bib0003) 2020; 78 Nassiri (10.1016/j.urology.2022.07.024_bib0012) 2018; 199 Jarow (10.1016/j.urology.2022.07.024_bib0013) 2016; 88 Stabile (10.1016/j.urology.2022.07.024_bib0004) 2021; 206 Aminsharifi (10.1016/j.urology.2022.07.024_bib0007) 2019; 2 Barret (10.1016/j.urology.2022.07.024_bib0006) 2014; 24 Lovegrove (10.1016/j.urology.2022.07.024_bib0020) 2020; 125 Onik (10.1016/j.urology.2022.07.024_bib0001) 2002; 60 Borges (10.1016/j.urology.2022.07.024_bib0016) 2021; 205 Natarajan (10.1016/j.urology.2022.07.024_bib0022) 2017; 198 Shah (10.1016/j.urology.2022.07.024_bib0021) 2021; 24 Jones (10.1016/j.urology.2022.07.024_bib0015) 2018; 199 Tay (10.1016/j.urology.2022.07.024_bib0019) 2019; 37 Epstein (10.1016/j.urology.2022.07.024_bib0025) 2016; 69 |
| References_xml | – volume: 199 start-page: 133 year: 2018 end-page: 139 ident: bib0015 article-title: High intensity focused ultrasound for radiorecurrent prostate cancer: A North American Clinical Trial publication-title: J Urol – volume: 13 start-page: 1 year: 2015 end-page: 6 ident: bib0017 article-title: The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer publication-title: World J Surg Oncol – volume: 205 start-page: 129 year: 2021 end-page: 136 ident: bib0016 article-title: Impact of focal versus whole gland ablation for prostate cancer on sexual function and urinary continence publication-title: J Urol – volume: 125 start-page: 853 year: 2020 end-page: 860 ident: bib0020 article-title: Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry publication-title: BJU Int – volume: 69 start-page: 428 year: 2016 end-page: 435 ident: bib0025 article-title: A contemporary prostate cancer grading system: a validated alternative to the gleason score publication-title: Eur Urol – volume: 65 start-page: 809 year: 2014 end-page: 815 ident: bib0011 article-title: Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen publication-title: Eur Urol – volume: 24 start-page: 567 year: 2021 end-page: 574 ident: bib0021 article-title: Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study publication-title: Prostate Cancer Prostatic Dis – volume: 206 start-page: 638 year: 2021 end-page: 645 ident: bib0004 article-title: Association between lesion location and oncologic outcomes after focal therapy for localized prostate cancer using either high intensity focused ultrasound or cryotherapy publication-title: J Urol – volume: 2 year: 2019 ident: bib0007 article-title: Diagnosis and management of local recurrence after prostate focal therapy: challenges and solutions publication-title: Eur Urol Oncol – volume: 81 start-page: 5 year: 2022 end-page: 33 ident: bib0002 article-title: An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? publication-title: Eur Urol – volume: 124 start-page: 431 year: 2019 end-page: 440 ident: bib0005 article-title: Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer publication-title: BJU Int – volume: 198 start-page: 839 year: 2017 end-page: 847 ident: bib0022 article-title: Focal laser ablation of prostate cancer: feasibility of magnetic resonance imaging-ultrasound fusion for guidance publication-title: J Urol – volume: 88 start-page: 8 year: 2016 end-page: 13 ident: bib0013 article-title: Partial gland ablation for prostate cancer: Report of a food and drug administration, American urological association, and society of urologic oncology public workshop publication-title: Urology – volume: 60 start-page: 109 year: 2002 end-page: 114 ident: bib0001 article-title: Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency publication-title: Urology – volume: 199 start-page: 453 year: 2018 end-page: 458 ident: bib0012 article-title: Focal therapy eligibility determined by magnetic resonance imaging/ultrasound fusion biopsy publication-title: J Urol – volume: 204 start-page: 941 year: 2020 end-page: 949 ident: bib0014 article-title: Hemigland cryoablation of clinically significant prostate cancer: intermediate-term followup via magnetic resonance imaging guided biopsy publication-title: J Urol – volume: 37 start-page: 397 year: 2019 end-page: 407 ident: bib0019 article-title: Surveillance after prostate focal therapy publication-title: World J Urol – volume: 18 start-page: e260 year: 2020 end-page: e265 ident: bib0009 article-title: Salvage focal cryotherapy offers similar short-term oncologic control and improved urinary function compared with salvage whole gland cryotherapy for radiation-resistant or recurrent prostate cancer publication-title: Clin Genitourin Cancer – volume: 78 start-page: 371 year: 2020 end-page: 378 ident: bib0003 article-title: Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an International Multidisciplinary Consensus publication-title: Eur Urol – volume: 191 start-page: 1764 year: 2014 end-page: 1769 ident: bib0018 article-title: Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer publication-title: J Urol – volume: 31 start-page: 564 year: 2017 end-page: 571 ident: bib0024 article-title: Propensity score-matched comparison of partial to whole-gland cryotherapy for intermediate-risk prostate cancer: an analysis of the cryo on-line data registry data publication-title: J Endourol – volume: 24 start-page: 241 year: 2014 end-page: 246 ident: bib0006 article-title: How to diagnose and treat focal therapy failure and recurrence? publication-title: Curr Opin Urol – volume: 29 start-page: 334 year: 2011 end-page: 342 ident: bib0010 article-title: Clinical application of a 3D ultrasound-guided prostate biopsy system publication-title: Urol Oncol – reference: Priester AM. Why does Focal Therapy for Prostate Cancer Fail? Manuscr Press, Los Angeles, 2022. – volume: 125 start-page: 853 year: 2020 end-page: 860 ident: bib0008 article-title: Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry publication-title: BJU Int – volume: 74 start-page: 422 year: 2018 end-page: 429 ident: bib0023 article-title: A multicentre study of 5-year outcomes following focal tgherapy in treating clinically significant nonmetastatic prostate cancer publication-title: Eur Urol – volume: 74 start-page: 422 year: 2018 ident: 10.1016/j.urology.2022.07.024_bib0023 article-title: A multicentre study of 5-year outcomes following focal tgherapy in treating clinically significant nonmetastatic prostate cancer publication-title: Eur Urol doi: 10.1016/j.eururo.2018.06.006 – volume: 60 start-page: 109 year: 2002 ident: 10.1016/j.urology.2022.07.024_bib0001 article-title: Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency publication-title: Urology doi: 10.1016/S0090-4295(02)01643-6 – volume: 2 year: 2019 ident: 10.1016/j.urology.2022.07.024_bib0007 article-title: Diagnosis and management of local recurrence after prostate focal therapy: challenges and solutions publication-title: Eur Urol Oncol – volume: 125 start-page: 853 year: 2020 ident: 10.1016/j.urology.2022.07.024_bib0020 article-title: Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry publication-title: BJU Int doi: 10.1111/bju.15004 – volume: 191 start-page: 1764 year: 2014 ident: 10.1016/j.urology.2022.07.024_bib0018 article-title: Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer publication-title: J Urol doi: 10.1016/j.juro.2013.12.036 – volume: 81 start-page: 5 year: 2022 ident: 10.1016/j.urology.2022.07.024_bib0002 article-title: An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? publication-title: Eur Urol doi: 10.1016/j.eururo.2021.08.005 – volume: 29 start-page: 334 year: 2011 ident: 10.1016/j.urology.2022.07.024_bib0010 article-title: Clinical application of a 3D ultrasound-guided prostate biopsy system publication-title: Urol Oncol doi: 10.1016/j.urolonc.2011.02.014 – volume: 124 start-page: 431 year: 2019 ident: 10.1016/j.urology.2022.07.024_bib0005 article-title: Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer publication-title: BJU Int doi: 10.1111/bju.14710 – volume: 199 start-page: 133 year: 2018 ident: 10.1016/j.urology.2022.07.024_bib0015 article-title: High intensity focused ultrasound for radiorecurrent prostate cancer: A North American Clinical Trial publication-title: J Urol doi: 10.1016/j.juro.2017.06.078 – volume: 13 start-page: 1 year: 2015 ident: 10.1016/j.urology.2022.07.024_bib0017 article-title: The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer publication-title: World J Surg Oncol doi: 10.1186/s12957-015-0753-9 – volume: 24 start-page: 567 year: 2021 ident: 10.1016/j.urology.2022.07.024_bib0021 article-title: Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/s41391-020-00315-y – volume: 88 start-page: 8 year: 2016 ident: 10.1016/j.urology.2022.07.024_bib0013 article-title: Partial gland ablation for prostate cancer: Report of a food and drug administration, American urological association, and society of urologic oncology public workshop publication-title: Urology doi: 10.1016/j.urology.2015.11.018 – volume: 31 start-page: 564 year: 2017 ident: 10.1016/j.urology.2022.07.024_bib0024 article-title: Propensity score-matched comparison of partial to whole-gland cryotherapy for intermediate-risk prostate cancer: an analysis of the cryo on-line data registry data publication-title: J Endourol doi: 10.1089/end.2016.0830 – volume: 18 start-page: e260 year: 2020 ident: 10.1016/j.urology.2022.07.024_bib0009 article-title: Salvage focal cryotherapy offers similar short-term oncologic control and improved urinary function compared with salvage whole gland cryotherapy for radiation-resistant or recurrent prostate cancer publication-title: Clin Genitourin Cancer doi: 10.1016/j.clgc.2019.11.009 – ident: 10.1016/j.urology.2022.07.024_bib0026 – volume: 69 start-page: 428 year: 2016 ident: 10.1016/j.urology.2022.07.024_bib0025 article-title: A contemporary prostate cancer grading system: a validated alternative to the gleason score publication-title: Eur Urol doi: 10.1016/j.eururo.2015.06.046 – volume: 78 start-page: 371 year: 2020 ident: 10.1016/j.urology.2022.07.024_bib0003 article-title: Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an International Multidisciplinary Consensus publication-title: Eur Urol doi: 10.1016/j.eururo.2020.05.018 – volume: 199 start-page: 453 year: 2018 ident: 10.1016/j.urology.2022.07.024_bib0012 article-title: Focal therapy eligibility determined by magnetic resonance imaging/ultrasound fusion biopsy publication-title: J Urol doi: 10.1016/j.juro.2017.08.085 – volume: 198 start-page: 839 year: 2017 ident: 10.1016/j.urology.2022.07.024_bib0022 article-title: Focal laser ablation of prostate cancer: feasibility of magnetic resonance imaging-ultrasound fusion for guidance publication-title: J Urol doi: 10.1016/j.juro.2017.04.017 – volume: 204 start-page: 941 year: 2020 ident: 10.1016/j.urology.2022.07.024_bib0014 article-title: Hemigland cryoablation of clinically significant prostate cancer: intermediate-term followup via magnetic resonance imaging guided biopsy publication-title: J Urol doi: 10.1097/JU.0000000000001133 – volume: 205 start-page: 129 year: 2021 ident: 10.1016/j.urology.2022.07.024_bib0016 article-title: Impact of focal versus whole gland ablation for prostate cancer on sexual function and urinary continence publication-title: J Urol doi: 10.1097/JU.0000000000001327 – volume: 37 start-page: 397 year: 2019 ident: 10.1016/j.urology.2022.07.024_bib0019 article-title: Surveillance after prostate focal therapy publication-title: World J Urol doi: 10.1007/s00345-018-2363-y – volume: 206 start-page: 638 year: 2021 ident: 10.1016/j.urology.2022.07.024_bib0004 article-title: Association between lesion location and oncologic outcomes after focal therapy for localized prostate cancer using either high intensity focused ultrasound or cryotherapy publication-title: J Urol doi: 10.1097/JU.0000000000001787 – volume: 65 start-page: 809 year: 2014 ident: 10.1016/j.urology.2022.07.024_bib0011 article-title: Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen publication-title: Eur Urol doi: 10.1016/j.eururo.2013.03.025 – volume: 125 start-page: 853 year: 2020 ident: 10.1016/j.urology.2022.07.024_bib0008 article-title: Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry publication-title: BJU Int doi: 10.1111/bju.15004 – volume: 24 start-page: 241 year: 2014 ident: 10.1016/j.urology.2022.07.024_bib0006 article-title: How to diagnose and treat focal therapy failure and recurrence? publication-title: Curr Opin Urol doi: 10.1097/MOU.0000000000000052 |
| SSID | ssj0006667 |
| Score | 2.4192035 |
| Snippet | To evaluate the near-term clinical and pathological effects of repeat partial gland ablation (PGA) in men with intermediate-risk prostate cancer (PCa).
One... To evaluate the near-term clinical and pathological effects of repeat partial gland ablation (PGA) in men with intermediate-risk prostate cancer... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 161 |
| SubjectTerms | Humans Image-Guided Biopsy - methods Male Prospective Studies Prostatic Neoplasms - pathology Quality of Life |
| Title | Partial Gland Ablation of Prostate Cancer: Effects of Repeat Treatment |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0090429522006173 https://dx.doi.org/10.1016/j.urology.2022.07.024 https://www.ncbi.nlm.nih.gov/pubmed/35907484 https://www.proquest.com/docview/2696864128 |
| Volume | 170 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEA6lgngR39ZHWcHrtjXJ5uGtFGtVWjwoeAvpJgsW2ZY-rv52Z3azLR5E8bjZDJvMzM5MkpkvhFzf3DirMipiYV2KoNoitszZ2FGdOCm1csV-x3AkBq_88S15q5FeVQuDaZXB9pc2vbDWoaUduNmevb9jja9GawoBROGHEfGTc4la3vrcpHlAeB5wMzsx9t5U8bQnrdW82LuGZSKlBYYn5T_5p5_iz8IP9ffIbgggo245xn1S8_kB2R6GI_JD0n_G4UOPe8xZjLrjMtktmmbRM1Z4QGwZ9VDU89uohC5e4DsIxMEqRy9V3vkRee3fvfQGcbgsIU4Z48s4tVw7D4spa7UYQ5vzWqaeMplpZnmaUt_h1iYqUyIFwXgmlFZ8zFmWSG81Oyb1fJr7UxJlXDBuHSwlkgx8HAhTayupF45LqRLfILxikUkDkjheaPFhqpSxiQmcNchZ05EGONsgrTXZrITS-I1AVPw3VZ0oWDYDxv43QrUm_KZMfyG9qgRt4EfD0xOb--lqYSjCCAkO_rxBTkoNWE-DJbjHoPjZ_z98TnbwqcyUuSD15XzlLyHeWY6bhUI3yVb34Wkw-gLac_9T |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb-IwEB61VNrtpeq-6Wuz0l5TqO340RtCpbAtiAOVerNM7EhUFVQU_n9nEofVHhCrXu2MEs8434ztmc8Av6-uvNMFk6l0PidSbZk67l3qmcm8Ukb7cr9jOJL9B_HnMXvcg25dC0NplRH7K0wv0Tq2tKI2Wy-zGdX4GkJTDCBKP8z34YDYqbIGHHQGd_3RBpAxQo_Ume2UBP4W8rSeLtfLcvsaV4qMlTSeTGxzUdtC0NIV9Y7hKMaQSaf6zE-wF-af4cMwnpJ_gd6YRoBP3FLaYtKZVvluyaJIxlTkgeFl0iVrL6-Tir34lfowFkdgTiZ16vlXeOjdTLr9NN6XkOaci1WaO2F8wPWUc0ZOsc0Ho_LAuCoMdyLPWWgL5zJdaJmjbQKX2mgxFbzIVHCGf4PGfDEPPyAphOTCeVxNZAW6ObSnMU6xIL1QSmehCaJWkc0jmTjdafFs66yxJxs1a0mztq0sarYJlxuxl4pNY5eArPVv61JRBDeLeL9LUG8E_5lP_yP6qza0xX-NDlDcPCzWr5YRk5AU6NKb8L2aAZth8Iy2GbQ4ef-Lf8LH_mR4b-8Ho7tTOKSeKnHmDBqr5TqcY_izml7E6f0Glg0CEw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Partial+Gland+Ablation+of+Prostate+Cancer%3A+Effects+of+Repeat+Treatment&rft.jtitle=Urology+%28Ridgewood%2C+N.J.%29&rft.au=Nassiri%2C+Nima&rft.au=Richardson%2C+Shannon&rft.au=Kuppermann%2C+David&rft.au=Brisbane%2C+Wayne+G&rft.date=2022-12-01&rft.issn=1527-9995&rft.eissn=1527-9995&rft.volume=170&rft.spage=161&rft_id=info:doi/10.1016%2Fj.urology.2022.07.024&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-4295&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-4295&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-4295&client=summon |